NEW YORK (GenomeWeb) – VolitionRx today announced a collaboration with ImmuneHealth on a pilot study to asses the feasibility of VolitionRx's technology for detecting prostate cancer. 

In the study, which was initiated today, ImmuneHealth, a Belgian contract research organization, will use VolitionRx's NuQ assays to analyze 120 blood samples from patients across four Belgian hospitals. Four groups of patients will assessed — those with aggressive prostate cancer; those with indolent prostate cancer; those with prostate hyperplasia; and negative controls. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Jay Shendure and his colleagues have developed a new method to more comprehensively identify human cell types, the NY Times reports.

Researchers in the UK and Japan have shown that infertility in mice with three sex chromosomes can be overcome, according to the Guardian.

China is embracing preimplantation genetic diagnosis, Nature News reports. 

In PLOS this week: host genetic factors associated with cervical neoplasia progression, population patterns for an ancient flowering rainforest plant, and more.